BioXcel Therapeutics, Inc. (BTAIQ)
OTCMKTS · Delayed Price · Currency is USD
0.0289
-0.0003 (-1.03%)
At close: Oct 16, 2026
BioXcel Therapeutics Revenue
BioXcel Therapeutics had revenue of $182.00K in the quarter ending June 30, 2026, with 51.67% growth. This brings the company's revenue in the last twelve months to $742.00K, down -14.52% year-over-year. In the year 2025, BioXcel Therapeutics had annual revenue of $642.00K, down -71.67%. That makes BioXcel Therapeutics the 44,053rd largest company in the world by revenue and 6,207th in the United States.
Revenue (ttm)
742.00K
Revenue Growth
-14.52%
P/S Ratio
1.22
Revenue / Employee
25.59K
Employees
29
Market Cap
904.73K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 642.00K | -1.62M | -71.67% |
| Dec 31, 2024 | 2.27M | 886.00K | 64.20% |
| Dec 31, 2023 | 1.38M | 1.01M | 268.00% |
| Dec 31, 2022 | 375.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Mystic Holdings | 21.40M |
| LiveWire Ergogenics | 571.68K |
| Herborium Group | 259.10K |
| Nutra Pharma | 258.91K |
| Full Alliance Group | 82.12K |
| American Green | 48.63K |
| Kaya Holdings | 26.69K |
BioXcel Therapeutics News
- 7 weeks ago - BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals - GlobeNewsWire
- 7 weeks ago - Biopharma firm BioXcel Therapeutics files for bankruptcy in US - Reuters
- 2 months ago - BioXcel Therapeutics Quarterly report: Q2 2026 - Filings
- 4 months ago - BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting - GlobeNewsWire
- 5 months ago - BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 5 months ago - BioXcel Therapeutics Quarterly report: Q1 2026 - Filings
- 5 months ago - BioXcel Therapeutics Earnings release: Q1 2026 - Filings
- 5 months ago - BioXcel Therapeutics Transcript: Investor update - Transcripts